During the PROTECT VIII main and extension studies

Long-term safety data with Jivi®1,2

Study Design Chart
  • As of January 2018 interim analysis.
  • Factor VIII inhibitor (1.7 BU/mL) was reported in one previously treated adult subject. Repeat testing did not confirm the presence of a Factor VIII inhibitor.
  • Overall AEs: 80.2% (n=97).